Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

8 Jul 2020

Abstract excerpt

We report a novel group of clinically aggressive spinal cord ependymomas characterized by Grade III histology, MYCN amplification, an absence of NF2 alterations or other recurrent pathogenic mutations, and a unique methylation classifier profile. Seven cases were found to have MYCN amplification in the course of routine mutational profiling of 552 patients with central nervous system tumors between December 2016...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32641156
DOI: 10.1186/s40478-020-00973-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaPMID 32641156Read ↗

Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomasSemantic proximity Read ↗

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.Semantic proximity Read ↗

Spinal low-grade ependymal tumors harboring telomerase reverse transcriptase promoter mutation and chromosome 7 gain with methylation profile of spinal subependymoma.Semantic proximity Read ↗

Genomic Landscape of Intramedullary Spinal Cord GliomasSemantic proximity Read ↗

Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing diseaseSemantic proximity Read ↗

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatmentSemantic proximity Read ↗

Expression alterations define unique molecular characteristics of spinal ependymomas.Semantic proximity Read ↗

Clinicopathologic analysis of multifocal myxopapillary ependymoma: Report of 4 cases and literature reviewSemantic proximity Read ↗

Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymomaSemantic proximity Read ↗

Genetic Markers and Mutations in Primary Spinal Cord Tumors and Their Impact on Clinical ManagementSemantic proximity Read ↗

Molecular subtyping of ependymoma and prognostic impact of Ki-67Semantic proximity Read ↗

Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.